Trastuzumab emtansine (solution)

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070) . Trastuzumab emtansine can be used for the research of advanced breast cancer[1][2].

Product Specifications

CAS Number

[1018448-65-1]

Product Name Alternative

Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; EGFR

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/trastuzumab-emtansine-solution.html

Purity

98.27

Solubility

10 mM in DMSO

Smiles

[Trastuzumabemtansine(solution)]

Molecular Weight

149114 (average)

References & Citations

[1]Verma S, et, al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367 (19) :1783-91.|[2]Menderes G, et, al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017 Oct;147 (1) :145-152.